Item 7.01. Regulation FD Disclosure.

On January 18, 2023, NanoVibronix, Inc. (the "Company"), issued a press release announcing an update on the efforts to expand access to the Company's PainShield product. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company undertakes no obligation to update, supplement or amend the materials attached hereto.

The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished pursuant to Item 7.01 and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise be subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit Number   Description

99.1               Press Release dated January 18, 2023 (furnished pursuant to
                 Item 7.01)
104              Cover Page Interactive Data File (formatted as Inline XBRL)

© Edgar Online, source Glimpses